Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SCN1A | P35498 | 1/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.44 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL448349 | 1.00 | CXCR4 (0.51) | CXCR4ALDH1A1SCN1ASCN2ASCN3A | |
| SCHEMBL1879610 | 1.00 | CXCR4 (0.51) | CXCR4ALDH1A1SCN1ASCN2ASCN3A | |
| SCHEMBL26576209 | 0.94 | CXCR4 (0.50) | CXCR4ALDH1A1SCN1ASCN2ASCN3A | |
| SCHEMBL292419 | 0.94 | HRH3 (0.46) | CXCR4HRH3 | |
| SCHEMBL292420 | 0.94 | HRH3 (0.46) | CXCR4HRH3 | |
| SCHEMBL8424204 | 0.90 | CXCR4 (0.44) | CXCR4ALDH1A1SCN1ASCN2ASCN3A | |
| SCHEMBL3323166 | 0.88 | ALDH1A1 (0.47) | CXCR4ALDH1A1HRH3 | |
| SCHEMBL17148079 | 0.88 | ALDH1A1 (0.47) | CXCR4ALDH1A1HRH3 | |
| SCHEMBL17142377 | 0.88 | ALDH1A1 (0.47) | CXCR4ALDH1A1HRH3 | |
| SCHEMBL23828669 | 0.87 | CXCR4 (0.57) | CXCR4ALDH1A1SCN1ASCN2ASCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491718-B2 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1648905-B1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | disclosed |
| CN-101054379-A | Pyrrole substituted pyrimidinone derivative, preparation method and use thereof in medicine | SHANGHAI HENGRUI MEDICINE CO L (CN) | 2007-10-17 | — | — | CN | disclosed |
| EP-1549613-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | Abbott Laboratories (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
| WO-2004033419-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | ABBOTT LABORATORIES (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | CXCR4 4161/4885ALDH1A1 3463/4885SCN1A 4216/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | CXCR4 4161/4885ALDH1A1 3463/4885SCN1A 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.